Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Etravirine (Intelence®) is recommended as an option for use within NHS Wales, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age. |
|||
|
|||
Medicine details |
|||
| Medicine name | etravirine (Intelence®) | ||
| Formulation | 25 mg tablet, 100 mg tablet, 200 mg tablet | ||
| Reference number | 1683 | ||
| Indication | In combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 3213 | ||
| NMG meeting date | 23/10/2013 | ||
| AWMSG meeting date | 20/11/2013 | ||
| Ratification by Welsh Government | 06/12/2013 | ||
| Date of issue | 13/12/2013 | ||
| Date of last review | 01/12/2016 | ||